Targeting Toll-like receptors 7 and 8 (TLR7/8) has emerged as a promising strategy in cancer immunotherapy. TLR7/8 agonists activate robust Th1-type immune responses and bridge innate and adaptive immunity. Further, TLR7/8 agonists can serve as valuable adjuncts to conventional therapies, such as chemotherapy and radiotherapy, enhancing efficacy while reducing adverse effects. Their integration into combination regimens for cancer offers a dual advantage: amplifying antitumor immunity and reducing tumor burden. Notably, the incorporation of TLR7/8 agonists into cancer vaccine platforms has yielded encouraging results in preclinical models and is advancing toward clinical application. This review highlights the mechanisms of action, therapeutic potential, and recent progress in the development of TLR7/8 agonist-based strategies for cancer treatment. We also discuss ongoing clinical evaluations and the rationale for combining these agents with existing modalities to enable more effective, personalized, and accessible cancer therapies.
靶向Toll样受体7和8（TLR7/8）已成为癌症免疫治疗中一种前景广阔的策略。TLR7/8激动剂能激活强烈的Th1型免疫应答，并桥接先天性与适应性免疫。此外，这类激动剂可作为化疗、放疗等传统疗法的重要辅助手段，在提升疗效的同时降低不良反应。将其整合至癌症联合治疗方案具有双重优势：既能增强抗肿瘤免疫，又可减轻肿瘤负荷。值得注意的是，将TLR7/8激动剂纳入癌症疫苗平台已在临床前模型中取得鼓舞人心的成果，并正逐步向临床应用推进。本综述重点阐述基于TLR7/8激动剂的癌症治疗策略的作用机制、治疗潜力及最新进展，同时探讨正在进行的临床评估工作，以及将这些药物与现有疗法联合应用的理论基础，旨在推动更有效、个性化且可及的癌症治疗方案的实现。
Enhancing Cancer Therapy with TLR7/8 Agonists: Applications in Vaccines and Combination Treatments
肿瘤(癌症)患者之家